publication date: Sep. 13, 2019

Guest Editorial

Why CAR-T policymaking is broken, and why we need to fix it

Michael Kolodziej

Michael Kolodziej

Vice president and

chief innovation officer,

ADVI Health 

 

Louis Jacques_1

Louis Jacques

Chief clinical officer and
senior vice president, ADVI Health

Former director of the Coverage and Analysis Group (CAG), Centers for Medicare and Medicaid Services

 

Marc Samuels

Marc Samuels

Chief executive officer,

ADVI Health

 

The initial reports of the near-miraculous benefits of CAR-T in pediatric acute lymphoblastic leukemia generated tremendous excitement—there was a Lazarus-like quality to these stories.

The occasional serious toxicity did give some pause, but there seemed to be a solution to this scary toxicity profile as physicians learned to care for these patients. And with the clinical reports … Continue reading Why CAR-T policymaking is broken, and why we need to fix it

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.